(688089)"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Progress of Litigation
Filed with SSE · Stock code 688089 · · 3 pages · Chinese
Summary by 6ix AI
CABIO Biotech (Wuhan) Co. Ltd. announced the progress of ongoing litigation regarding a commercial secret dispute. The company received a ruling from the Supreme People's Court rejecting the request for a retrial by the plaintiff. This ruling does not affect the company's previously won judgment and will not impact its current or future profits. The announcement includes important risk warnings related to the litigation's status and potential implications for the company.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
CABIO Biotech (Wuhan) Co. Ltd. on 6ix
Story so far
- (688089)"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Progress of the Imposition of Other Risk Warning on the Company's Shares
- (688089)"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Provision for Credit and Asset Impairment for the First Three Quarters of 2026
- (688089)"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Resignation of the Securities Affairs Representative
Earlier from CABIO Biotech (Wuhan)
- (688089)"Cabio Biotech (Wuhan) Co., Ltd."Report for Q3 2026
- (688089)"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Provision for Credit and Asset Impairment for the First Three Quarters of 2026
- (688089)"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Progress of the Imposition of Other Risk Warning on the Company's Shares
- (688089)"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Resignation of the Securities Affairs Representative
- Announcement on Receipt of the Notice of Response to Retrial and Progress of Litigation
Follow CABIO Biotech (Wuhan) into a list and get an email when it puts out news.
Follow CABIO Biotech (Wuhan)